Regeneron’s prostate cancer bispecific antibody trial has been halted due to two deaths

Taiho Oncology’s LONSURF received the FDA’s nod for CRC in combination with Bevacizumab

Actuate Therapeutics received the FDA ODD for Elraglusib for the treatment of Pancreatic Cancer

Francis Medical received the FDA Breakthrough Device Designation for Vanquish Minimally Invasive Prostate Cancer Therapy